Catena Biosciences

Next-gen Protein Coupling

Catena Biosciences is using protein-coupling technology to cure autoimmune disorders. Protein-protein and protein-peptide conjugates are valuable for constructing vaccines, immunotherapies and signaling molecules. Catena’s patented technology allows the attachment of proteins faster and more selectively than any current competing method. Catena’s approach joins together, with the aid of the enzyme tyrosinase, the naturally incorporated amino acids tyrosine and cysteine, making the technology widely applicable. The advantages of this natural form of protein conjugation over genetic fusions or chemical attachment is that it preserves native protein function and requires minimal engineering. Catena is hoping to couple receptor proteins to control immune responses.